Lpath, Inc. (LPTN.OB) Announces Successful Administration of Phase 1 iSONEP
A leader in lipidomics-based therapeutics, Lpath, Inc. announced today that it has completed the enrollment and dosing of 15 wet AMD patients in a multi-center, open label, single-arm Phase 1 study of iSONEP. The iSONEP was administered as a single intravitreal injection to the study eye. The company is expected to release a complete analysis of efficacy when all data becomes available. All 15 patients tolerated the drug well, and there were no drug-related serious events reported at any of the five dose levels. Additionally, several patients showed a reduction in retinal thickness and regression of lesion size, two primary…